N-Sulfoconjugation is a common metabolic pathway of amine compounds in vivo. In the present study, we investigated the N-sulfation of quinolones and other amine drugs (ciprofloxacin, moxifloxacin, garenoxacin, desipramine, and metoclopramide) to assess the contribution of specific human cytosolic sulfotransferases (SULTs) to the reactions using purified recombinant enzymes and human liver cytosols (HLCs). Among the enzymes examined, human (h) SULT2A1 exhibited N-sulfoconjugation activities toward all drugs tested, whereas the other five different forms (hSULT1A1, hSULT1A3, hSULT1B1, hSULT1C2, and hSULT1E1) showed no detectable activities except hSULT1A1 for garenoxacin sulfation. The N-sulfoconjugating activity of hSULT2A1 was highest toward moxifloxacin ( 
Sulfate conjugation catalyzed by cytosolic sulfotransferases (SULTs) is a primary metabolic pathway of xenobiotics and endogenous compounds such as hormones and neurotransmitters. SULTs catalyze a transfer of a sulfonyl group from 3Ј-phosphoadenosine 5Ј-phosphosulfate (PAPS) to hydroxyl or amine groups of acceptor substrates (Yamazoe and Kato, 1995) . SULTs constitute a gene superfamily, which contains at least six different classes (i.e., SULT1-6 families in mammals) based on their identities of deduced amino acid sequences (Nagata et al., 2005; Lindsay et al., 2008) . Enzymatic properties of SULTs have also been investigated, particularly with those in SULT1 and SULT2 families. Members of the SULT1 family prefer phenolic compound as substrates, whereas SULT2 family members catalyze sulfation of hydroxyl groups of steroids, such as androsterone, allopregnanolone, and dehydroepiandrosterone (DHEA) (Yamazoe and Kato, 1995; Nagata et al., 2005) .
Several amine compounds have long been found to be excreted as sulfamates in the urine of mammals (Boyland and Sims, 1959; Iwasaki et al., 1986) . Enzymes mediating amine sulfation were isolated from the livers of guinea pigs (Ramaswamy and Jakoby, 1987) and rats (Naritomi et al., 1994) . Both enzymes catalyzed O-sulfation as well as N-sulfation to similar extents. The rat form is judged to associate with the SULT2 family because of the similarity of its N-terminal amino acid sequence to those of SULT2 enzymes (Naritomi et al., 1994) . Previously we reported the purification and molecular cloning of a novel SULT catalyzing the sulfation of amine compounds from rabbits (Yoshinari et al., 1998a; Shiraga et al., 1999b) . The enzyme constitutes a SULT gene family distinct from SULT1 and SULT2, and thus the enzyme has been termed SULT3A1 (ST3A1) 1 (Yoshinari et al., 1998a ). The rabbit SULT3A1 shows selective activities to amine compounds to form sulfamates, but little O-sulfating activity (Yoshinari et al., 1998a; Shiraga et al., 1999b) . More recently, two mouse amine N-sulfotransferases, designated Sult3a1 and Sult3a2, have been cloned and characterized with bacterially expressed recombinant proteins (Takahashi et al., 2008) . Similar to rabbit SULT3A1, both mouse enzymes were capable of sulfating amino groups of substrates. Thus, enzymatic properties of SULT3A family members are consistent among animal species.
As for other mammals, the conjugation of amino groups with sulfate is a well known metabolic process for amine compounds in 1 The nomenclature of individual SULT forms is based on the Human Genome Nomenclature Committee. The names in the nomenclature system proposed by us with "ST" as a prefix (Nagata et al., 2005) are included in the text. Their accession numbers are as follows: ST1A3/hSULT1A1, NM_001055; ST1A5/ hSULT1A3, NM_003166; ST1B2/hSULT1B1, NM_014465; ST1C2/hSULT1C2, NM_001056; ST1E4/hSULT1E1, NM_005420; and ST2A3/hSULT2A1, NM_003167.
humans (Stillwell et al., 1994; Shiraga et al., 1999a) . Several quinolone antibacterial drugs with amino groups are metabolized by N-sulfoconjugation and excreted in urine, feces, or bile. Approximately 10 to 20% of a single intravenous or oral dose of ciprofloxacin is eliminated as its N-sulfate (Bacracheva et al., 1991; Krol et al., 1995) . Moxifloxacin also undergoes sulfation. Its N-sulfate metabolite detected in urine and feces of healthy volunteers after a single intravenous or oral dose of moxifloxacin accounts for 2.4 and 35% of the dose, respectively (Moise et al., 2000) . Likewise, the main metabolite of garenoxacin is N-sulfate conjugate. Approximately, 5% of a single intravenous or oral dose is excreted via urine as garenoxacin sulfate Hayakawa et al., 2003) . For trovafloxacin, approximately 4.1% of the drug is metabolized by N-sulfoconjugation (Vincent et al., 1998) . These data suggest a major role of N-sulfation in the disposition of quinolones. However, humans have no SULT3 family enzyme, and there is no information on the role of specific human SULT(s) in the sulfation of these antibacterial drugs. In the present study, we investigated the N-sulfation of several quinolones including ciprofloxacin, moxifloxacin, and garenoxacin to assess the contribution of specific human SULTs to the reaction using recombinant enzymes and human liver cytosols. Besides these quinolones, other amine drugs, desipramine and metoclopramide, have also been examined. These drugs were previously reported to be metabolized to N-sulfoconjugates in humans (Bateman et al., 1980; Romiti et al., 1992) . Our present results clearly demonstrate that human SULT2A1 (hSULT2A1, ST2A3) is exclusively responsible for the N-sulfation of amine-containing quinolone drugs in the body.
Materials and Methods
Materials. Ciprofloxacin, desipramine, DHEA, metoclopramide hydrochloride, bovine serum albumin, and PAPS were purchased from Sigma-Aldrich . Nickel-nitrilotriacetic acid agarose was the product of QIAGEN (Valencia, CA). SDS-polyacrylamide gel electrophoresis molecular weight standards were purchased from Bio-Rad (Hercules, CA). All other chemicals used were of the highest grade available.
Recombinant Human Sulfotransferases and Human Liver Cytosols. hSULT1E1 (ST1E4) (Honma et al., 2002) and hSULT2A1 (Honma et al., 2002) were expressed as a histidine-tagged protein, designated His 6 -SULT, and purified from Escherichia coli cytosols with nickel-nitrilotriacetic acid agarose as described previously (Senggunprai et al., 2008) . Other SULTs including hSULT1A1 (ST1A3), hSULT1A3 (ST1A5), hSULT1B1 (ST1B2), and hSULT1C2 (ST1C2) were previously expressed and purified (Senggunprai et al., 2008) . Protein concentrations of the recombinant enzymes were determined by spectrophotometry and calculated based on their extinction coefficient (Gill and von Hippel, 1989 ). All of the purified proteins migrated as a single band corresponding to their predicted molecular weight and were at least 99% pure as evaluated by SDS-polyacrylamide gel electrophoresis (data not shown). Human liver cytosols (HLCs) (n ϭ 6) were prepared as described previously (Honma et al., 2002) . Experiments with human samples were approved by the Ethical Committee of Graduate School of Pharmaceutical Sciences, Tohoku University.
Sulfation Assay and Kinetic Analysis. Sulfating activities were determined from the radioactivities of the metabolites obtained with [
35 S]PAPS as a sulfate donor after thin-layer chromatography as described previously (Yoshinari et al., 1998b; Senggunprai et al., 2008) with slight modification. All enzyme assays were conducted under conditions in which the linearity with respect to protein concentration was obtained. In addition, assay conditions were optimized to ensure initial rate conditions. A typical incubation mixture consisted of 0.1 M potassium phosphate buffer (pH 7.4 for DHEA, ciprofloxacin, moxifloxacin, and garenoxacin) or 50 mM Tris-HCl buffer (pH 10.0 for desipramine and metoclopramide), 1 mM dithiothreitol, 5 mM MgCl 2 , 1 mg/ml 
TABLE 1

Sulfating activities toward various amine drugs of human recombinant SULTs
Sulfating activities were determined using ͓ 35 S͔PAPS as a sulfate donor. Reactions were performed at pH 7.4 (for ciprofloxacin, moxifloxacin, and garenoxacin) or pH 10.0 (for desipramine and metoclopramide) in the presence of 100 M concentrations of substrates and 50 ng of recombinant enzymes (His 6 -SULT). After a 20-min incubation, reaction mixtures were separated on thin-layer plates. The radioactive spots were quantified with an FLA-3000 image analyzer. The data are expressed as the mean Ϯ S.D. of three determinations from one experiment.
SULT Sulfating Activity
Ciprofloxacin
, not detected (activity below the detection limit: 0.1 nmol/min/mg protein).
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at ASPET Journals on June 20, 2017 dmd.aspetjournals.org bovine serum albumin, 10 M [ 35 S]PAPS (0.4 Ci/mmol), 0.5 to 5 g/ml His 6 -SULT protein or 0.25 mg/ml HLC, and various concentrations of substrates in the final volume of 10 l. The reaction was initiated by addition of [ 35 S]PAPS and terminated by addition of 5 l of ice-cold acetonitrile after incubation at 37°C for 7 min (for DHEA) or 20 min (for others). Portions (10 l) of the reaction mixture were spotted on a thin-layer plate (thin-layer chromatography aluminum plate silica gel 60 F 254 , 250 m; Merck, Darmstadt, Germany). The metabolites of ciprofloxacin, moxifloxacin, garenoxacin, and metoclopramide were developed with a solvent system of n-butanol-acetic acid-water (4:1:2), and those of DHEA and desipramine were developed with chloroform-methanol-water-28% ammonia aqueous (60:35:7.5:0.5). The radioactive spots were analyzed with an FLA-3000 image analyzer (FujiFilm, Tokyo, Japan). Analyses to determine apparent kinetic parameters were performed with various substrate concentrations ranging from 0.05 to 5 M for DHEA, 50 M to 3 mM for ciprofloxacin and moxifloxacin, 10 M to 1.5 mM for garenoxacin, 1 M to 1 mM for desipramine, and 100 M to 10 mM for metoclopramide.
Data Analysis. Apparent kinetic parameters, K m and V max values, and correlation coefficients (r) were determined using the Prism 5 program (GraphPad Software Inc., San Diego, CA).
Results
Sulfating Activities and Kinetic Characterization of Human
Recombinant SULTs against Amine Drugs. As mentioned in the previous studies, amine N-sulfating activities exhibit pH dependence (Ramaswamy and Jakoby, 1987; Yoshinari et al., 1998a; Shiraga et al., 1999b) probably because the sulfation occurs on unprotonated forms of amines. In fact, high activities were detected at a physiological pH of 7.4 for N-sulfation assays with amphoteric drugs, ciprofloxacin, moxifloxacin, and garenoxacin, in this study. On the other hand, the assays were carried out at pH 10 for basic amines desipramine and metoclopramide, with their pK a values of 10.4 and 9.1, respectively. The sulfating activities detected at pH 7.4 with hSULT2A1 were approximately 35 and 20 times lower than those at pH 10 for desipramine and metoclopramide, respectively, at a substrate concentration of 100 M (data not shown).
N-Sulfating activities of human SULTs (hSULT1A1, hSULT1A3, hSULT1B1, hSULT1C2, hSULT1E1, and hSULT2A1) toward quinolones and other amine drugs (Fig. 1) were determined, and the results are presented in Table 1 . Among the enzymes investigated, only hSULT2A1 exhibited N-sulfoconjugation activities toward all of the substrates tested, whereas other SULTs showed no detectable activities under the condition used (100 M) except the noticeable activity of hSULT1A1 for garenoxacin sulfation. The N-sulfoconjugating activity of hSULT2A1 was highest toward moxifloxacin (6.3 Ϯ 0.1 nmol/min/mg protein) and lowest toward metoclopramide (0.29 Ϯ 0.04 nmol/min/mg protein).
The apparent kinetic parameters for the hSULT2A1-mediated N-sulfation of the amine drugs and O-sulfation of DHEA, a typical substrate of the enzyme, were then determined ( Table 2 ). The kinetics of O-and N-sulfation of substrates were modeled using typical Michaelis-Menten or substrate inhibition equations (Fig. 2) . Goodness of fit and other parameters (e.g., the plausibility of best-fit values, 95% confidence intervals, and others) were compared between these two equations. The kinetics of O-and N-sulfation of all substrates fit well to a typical Michaelis-Menten equation, except those of metoclopramide, which fit better to a substrate inhibition equation (Fig. 2) . hSULT2A1 catalyzed DHEA sulfation with high affinity as indicated by a very low K m value (0.89 Ϯ 0.05 M). On the other hand, the K m values for N-sulfation of the amine compounds mediated by hSULT2A1 were relatively high compared with that for O-sulfation of DHEA (ciprofloxacin, 1.08 Ϯ 0.03 mM; moxifloxacin, 0.53 Ϯ 0.01 mM; garenoxacin, 0.19 Ϯ 0.01 mM; desipramine, 0.054 Ϯ 0.001 mM; and metoclopramide, 2.32 Ϯ 0.12 mM). The high K m value (Ͼ1 mM, 
Apparent kinetic parameters for sulfation of DHEA and various amine compounds by hSULT2A1 and HLCs
Assays were performed as described in the legend to Table 1 we could not determine exactly because of a limitation in solubility) was observed for hSULT1A1-catalyzed garenoxacin sulfation as well. Among amines tested, the V max value of hSULT2A1-mediated N-sulfation reaction was highest for ciprofloxacin sulfation (62.7 Ϯ 4.9 nmol/min/mg protein) and lowest for desipramine sulfation (3.5 Ϯ 0.8 nmol/min/mg protein). Kinetic Characterization of HLCs against DHEA and Amine Drugs. The kinetic analyses were further performed with HLCs (n ϭ 3), and the results are summarized in Table 2 . Plots of metabolite formation versus substrate concentration for DHEA and amine sulfations by all HLCs showed saturable hyperbolic curves, and EadieHofstee plots exhibited monophasic kinetics (Fig. 3) . The sulfation reactions for all substrates were fit to a typical Michaelis-Menten equation, except those for DHEA and metoclopramide, which were fit well to a substrate inhibition equation. The K m value for N-sulfation of each amine compound mediated by HLCs was of similar levels with that by hSULT2A1. Those values ranged from 1.36 Ϯ 0.18 to 1.65 Ϯ 0.29 mM for ciprofloxacin, 0.35 Ϯ 0.06 to 0.42 Ϯ 0.09 mM for moxifloxacin, 0.12 Ϯ 0.01 to 0.15 Ϯ 0.01 mM for garenoxacin, 0.11 Ϯ 0.007 to 0.17 Ϯ 0.003 mM for desipramine, and 0.87 Ϯ 0.01 to 1.88 Ϯ 0.34 mM for metoclopramide.
Correlation Analysis between O-and N-Sulfating Activities of HLCs. To confirm the contribution of hSULT2A1 for N-sulfoconjugation, correlation analyses between N-sulfating activities toward amine drugs and O-sulfating activity toward DHEA were performed with HLCs (n ϭ 6). As shown in Fig. 4 , the correlation between O-sulfating activity to DHEA and N-sulfating activity to each amine drug was very high and significant (ciprofloxacin, r ϭ 0.99, p Ͻ 0.0001; moxifloxacin, r ϭ 0.96, p ϭ 0.003; garenoxacin, r ϭ 0.96, p ϭ 0.0006; desipramine, r ϭ 0.95, p ϭ 0.003; and metoclopramide, r ϭ 0.93, p ϭ 0.008).
Discussion
Several quinolones are known to be biotransformed to their sulfamates before excretion. In the present study, we have assessed the contribution of specific human SULT forms to N-sulfoconjugation of quinolones and other amine drugs (i.e., desipramine and metoclopramide) (Fig. 1) .
Among the enzymes investigated, hSULT2A1 prominently showed N-sulfoconjugating activities toward all drugs tested, whereas other SULTs showed no detectable activities under the conditions used except hSULT1A1 for garenoxacin sulfation. To clarify whether hSULT2A1 was specifically involved in the N-sulfation of aminecontaining drugs in human livers, the kinetic characteristics for N-sulfation of amines mediated by the enzyme were compared with those mediated by HLCs. The kinetics of N-sulfations in HLCs were monophasic (Fig. 3) , suggesting that a single SULT is responsible for each reaction. The K m value for the sulfation of each amine drug mediated by HLCs was similar to that by hSULT2A1, indicating that hSULT2A1 is mainly responsible for the N-sulfoconjugation of amine drugs in human livers. The specific contribution of hSULT2A1 was also corroborated by the high and significant correlation observed between N-sulfating activities toward amine drugs and O-sulfating activity toward DHEA, a hSULT2A1 probe substrate, mediated by HLCs. Thus, the results from kinetic assays and correlation analyses, together with the substantial level of hSULT2A1 found in liver (Luu-The et al., 1995) , unequivocally show that hSULT2A1 is the enzyme responsible for the N-sulfoconjugation of quinolones and possibly other amine drugs in human liver.
The present results, in addition to previous reports in rats (Iwasaki et al., 1986) , guinea pigs (Ramaswamy and Jakoby, 1987) , and rabbits (Yoshinari et al., 1998a; Shiraga et al., 1999b) , have demonstrated that a wide variety of amine compounds, including alicyclic amines, alkylamines, and arylamines, serve as substrates for N-sulfation, despite large differences in their overall structures. Both primary and secondary, but not tertiary, amines are subjected to N-sulfoconjugation. For the quinolone drugs used in this study, secondary alicyclic amines indicated by the asterisks in Fig. 1 are N-sulfoconjugated (Krol et al., 1995; Moise et al., 2000; Fukumoto et al., 2003) , whereas metoclopramide is sulfated at the 4-primary aromatic heterocyclic amino group (Bateman et al., 1980) . Conversely, the position sulfated in desipramine constitutes a secondary alkylamine (Fig. 1) (Iwasaki et al., 1986; Ramaswamy and Jakoby, 1987) . Therefore, structurally divergent amines act as an acceptor substrate for the N-sulfoconjugation process in animals and in humans.
Previously intense variation in the activity of desipramine N-sulfation in human liver was reported (Romiti et al., 1992) . In the present study, we also observed a considerable variation in the activities of N-and O-sulfation among the HLCs used throughout the substrates tested. It has been reported that hepatic hSULT2A1 activity varies more than 5-fold without gender dependence (Aksoy et al., 1993) and that the amount of hSULT2A1 protein varies remarkably among liver samples (Duanmu et al., 2006) . Thus, interindividual differences in hSULT2A1 activity may contribute to variability in the plasma concentration of drugs metabolized by this enzyme through N-sulfation as well as O-sulfation.
hSULT2A1 has long been known as an enzyme mediating O-sulfation of many hydroxysteroid substrates, such as bile acids, pregnenolone, estrogens, DHEA, and other hormonal and xenobiotic alcoholic substrates (Falany et al., 1994; Yamazoe and Kato, 1995) . The enzyme is also involved in the metabolism of several therapeutic drugs including tibolone (Falany et al., 2004) , raloxifene , 4-hydroxytamoxifen , and budesonide (Meloche et al., 2002) . The conjugations of these drugs with a sulfonyl moiety result in a loss of their pharmacological activities and an increase in water solubility and excretion. In the present study, we have demonstrated that amine-containing drugs are also substrates for hSULT2A1. Thus, a broad spectrum of compounds serve as substrates for hSULT2A1.
In conclusion, we have demonstrated that N-sulfation of quinolones and other amine-containing therapeutic drugs is mediated by SULT2A1 in humans, who lack the SULT3A subfamily enzyme. Given that hSULT2A1 catalyzes O-sulfation of numbers of drugs and FIG. 3 . Kinetic analysis of DHEA and amines sulfations by HLC. Sulfating activities were determined as described in the legend to Table 2 . The plots of metabolite formation versus substrate concentration and Eadie-Hofstee (inset) of a single representative HLC are shown. Each plot depicts the mean of duplicate determinations in one typical experiment of three experiments.
N-SULFOCONJUGATION OF AMINE DRUGS BY SULT2A1
at ASPET Journals on June 20, 2017 dmd.aspetjournals.org environmental chemicals, the enzyme plays an essential role in the protection of the human body from such xenobiotics.
